The American Cancer Society and Stand Up To Cancer (SU2C), an initiative of the Entertainment Industry Foundation, have announced a partnership to advance research efforts in the fight against cancer.
To that end, each organization has committed $10 million over three years toward their first project, the creation of a "dream team" of researchers focused on developing new therapies for lung cancer, to which Bristol-Myers Squibb will provide $5 million through SU2C. Later this year, the American Association for Cancer Research, an SU2C partner, will issue a call for research proposals, with members of the team to be announced in 2015. Lung cancer is the leading cause of cancer death among both men and women in the United States, claiming the lives of approximately 160,000 people annually.
The collaboration between the two organizations also will include advocacy efforts led by SU2C and the American Cancer Society Cancer Action Network, the cancer society's 501(c)(4) affiliate. "The American Cancer Society has been on the forefront of the battle against this insidious disease for more than a hundred years; its millions of volunteers are literally the boots on the ground in this fight," said SU2C co-founder and EIF president/CEO Lisa Paulsen. "We're honored to collaborate with an organization with such a rich history in the research, education, and advocacy arenas."
"SU2C was started by the entertainment community and has had tremendous success in heightening the public's awareness of the great promise of today's cancer research," said John R. Seffrin, CEO of the American Cancer Society. "This alliance marries the society's comprehensive cancer-fighting mission with SU2C's high-impact funding model. Collectively, the society and SU2C can push ahead more quickly with cutting-edge research on some of the most deadly cancers, all for the benefit of patients."